LLC NPO Petrovax Pharm (hereinafter referred to as the Company or Petrovax) announces changes in the membership. Petrovax President Mikhail Tsyferov and investment company VB Partners are buying out 100% of the Company from Interros Holding using their own and borrowed funds from a consortium of banks. Thus, the previous owner completely withdraws from the business of Petrovax.
The parties did not disclose the structure and amount of the transaction.
Mikhail Tsyferov has been heading Petrovax since 2018. As a result of the transaction, Mikhail will fully focus on the management of the company, leaving other positions
Participation in the transaction of the investment company VB Partners will contribute to the realization of Petrovax potential. The company's strategy is aimed at creating and investing in sustainable businesses with a clear business model and effective management - which fully reflects the vision of both the Petrovax team and the selling party.
Petrovax is a Russian full-cycle biotechnology company with 25 years of successful experience in the pharmaceutical market. The product portfolio includes proprietary originators, localized medicines and vaccines, as well as generics and dietary supplements. The company has its own research and development center and an investment program for R&D, is the owner of patents in Russia and abroad for molecules and production technologies. A modern production complex for the production of substances and finished dosage forms in the Moscow Region operates in accordance with international GMP standards. Petrovax is Russia's largest exporter of original medicines and vaccines; drugs are supplied to 12 countries of the EAEU and the EU. Petrovax's partners are leading international pharmaceutical companies: Pfizer, Abbott, Boehringer Ingelheim, ISU ABXIS.
The company's investment strategy is aimed at the development, development of production and import substitution of drugs used to treat socially significant diseases, such as oncological, autoimmune, infectious and orphan diseases.